ONO Golden Ticket 2024 Winner

ONO and MBC BioLabs are delighted to announce DeepSeq.AI as the winner of their 2024 Golden Ticket Competition. Congratulations to the DeepSeq.AI team! 

DeepSeq.AI uses its custom AI platform to enable pharmaceutical companies to develop highly novel, functional, and manufacturable large molecule drugs, using an explainable Generative AI-based approach that optimizes multiple functions with proprietary large-scale wet-lab screening methods. Specifically, DeepSeq.AI models protein “grammar,” optimizing protein drug discovery with respect to conditional binding, manufacturability, efficacy, etc. Unlike most pre-seed startups, DeepSeq.AI already has a strong commercial product validated by paying customers (including a top 10 biopharma), with its platform protected by a granted patent. DeepSeq.AI’s approach has been further validated by investments from prominent biotech accelerators Merck DSS and UC-Berkeley Skydeck, and the company has also recently received an NSF SBIR grant.

⟶ DeepSeq.ai website

Ono Pharmaceutical Co., Ltd., headquarterd in Osaka, is an R&D-oriented pharmaceutical company committed to creating innovative medicines in specific areas. Ono focuses its research on the oncology, immunology, neurology and specialty research with high medical needs as priority areas for discovery and development of innovative medicines. For further information, please visit the company’s website at https://www.ono-pharma.com/.